These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 7877657)

  • 21. Recent advances in bladder cancer diagnostics.
    Sanchez-Carbayo M
    Clin Biochem; 2004 Jul; 37(7):562-71. PubMed ID: 15234237
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clear cell carcinoma of the urinary bladder.
    Lum D
    Pathology; 2006 Aug; 38(4):367-70. PubMed ID: 16916733
    [No Abstract]   [Full Text] [Related]  

  • 23. Autoantibodies against P53 protein in patients with transitional cell carcinoma of the bladder.
    Sanchez-Carbayo M; Chulia MT; Niveiro M; Aranda I; Mira A; Soria F
    Anticancer Res; 1999; 19(4C):3531-7. PubMed ID: 10629648
    [TBL] [Abstract][Full Text] [Related]  

  • 24. p53 and RB: simple interesting correlates or tumor markers of critical predictive nature?
    Cordon-Cardo C
    J Clin Oncol; 2004 Mar; 22(6):975-7. PubMed ID: 14981108
    [No Abstract]   [Full Text] [Related]  

  • 25. [Role of Ki-67, mutated gene-suppressor p53 and HER-2neu oncoprotein in the prognosis for the clinical course of bladder cancer].
    Masliukova EA; Pozharisskiĭ KM; Karelin MI; Startsev VIu; Ten VP
    Vopr Onkol; 2006; 52(6):643-8. PubMed ID: 17338241
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The mechanism and clinical applications of the NMP22 tumor marker immunoassay: a review.
    Sawczuk IS; Lee B
    Am Clin Lab; 1999 Apr; 18(3):24-6. PubMed ID: 10538149
    [No Abstract]   [Full Text] [Related]  

  • 27. P21-activated kinase 1: a new molecular marker for intravesical recurrence after transurethral resection of bladder cancer.
    Ito M; Nishiyama H; Kawanishi H; Matsui S; Guilford P; Reeve A; Ogawa O
    J Urol; 2007 Sep; 178(3 Pt 1):1073-9. PubMed ID: 17644138
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Superficial bladder cancer: the role of molecular markers in the treatment of high-risk superficial disease.
    Malkowicz SB
    Semin Urol Oncol; 1997 Aug; 15(3):169-78. PubMed ID: 9394912
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The prognostic value of p53 nuclear overexpression and MIB-1 as a proliferative marker in transitional cell carcinoma of the bladder.
    Popov Z; Hoznek A; Colombel M; Bastuji-Garin S; Lefrere-Belda MA; Bellot J; Abboh CC; Mazerolles C; Chopin DK
    Cancer; 1997 Oct; 80(8):1472-81. PubMed ID: 9338472
    [TBL] [Abstract][Full Text] [Related]  

  • 30. p53 and p21 Expression levels predict organ preservation and survival in invasive bladder carcinoma treated with a combined-modality approach.
    Garcia del Muro X; Condom E; Vigués F; Castellsagué X; Figueras A; Muñoz J; Solá J; Soler T; Capellà G; Germà JR
    Cancer; 2004 May; 100(9):1859-67. PubMed ID: 15112266
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combined assay of CYFRA21-1, telomerase and vascular endothelial growth factor in the detection of bladder transitional cell carcinoma.
    Bian W; Xu Z
    Int J Urol; 2007 Feb; 14(2):108-11. PubMed ID: 17302565
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The prevalence and clinicopathologic correlate of p16INK4a, retinoblastoma and p53 immunoreactivity in locally advanced urinary bladder cancer.
    Tzai TS; Tsai YS; Chow NH
    Urol Oncol; 2004; 22(2):112-8. PubMed ID: 15082007
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Tumor bladder antigen (TBA). A new method for the diagnosis and detection of recurrence of bladder cancer].
    Escaf Barmadah S; Martín Benito JL; Fernández Gómez JM; San Martín Blanco A; Pérez Gracia FJ; Rodríguez Martínez JJ
    Arch Esp Urol; 1998 Mar; 51(2):129-36. PubMed ID: 9586309
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cathepsin B, p53 expression and AgNORs in transitional cell carcinoma.
    Akpolat I; Bariş YS; Yilmaz AF; Bakirtaş M; Saylik A; Karagöz F; Kandemir B
    Neoplasma; 1998; 45(6):365-8. PubMed ID: 10210109
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Telomerase: a potential marker of bladder transitional cell carcinoma in bladder washes.
    Lee DH; Yang SC; Hong SJ; Chung BH; Kim IY
    Clin Cancer Res; 1998 Mar; 4(3):535-8. PubMed ID: 9533519
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular prognostic factors in bladder cancer.
    Schalken JA
    Eur Urol; 1998; 33 Suppl 4():13-4. PubMed ID: 9615200
    [No Abstract]   [Full Text] [Related]  

  • 37. "Wildcatting" for breakthroughs in urothelial cancer detection and management--a frustrating business.
    Walther PJ
    J Urol; 1995 Oct; 154(4):1348-50. PubMed ID: 7544837
    [No Abstract]   [Full Text] [Related]  

  • 38. [Leukocyte adherence inhibition assay for the diagnosis of bladder cancer].
    Xu JN; Li YT; Zhang ZY
    Zhonghua Wai Ke Za Zhi; 1985 Mar; 23(3):148-51, 190. PubMed ID: 3996113
    [No Abstract]   [Full Text] [Related]  

  • 39. HpD photodetection of bladder carcinoma.
    Lin CW; Bellnier DA; Fujime M; Prout GR
    Prog Clin Biol Res; 1984; 170():187-99. PubMed ID: 6241676
    [No Abstract]   [Full Text] [Related]  

  • 40. Biomarkers for transitional cell carcinoma-pro.
    Grossman HB
    Urology; 2001 May; 57(5):847-8. PubMed ID: 11337279
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.